Larazotide acetate — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 3 sources[1,2,3].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Related impurities in peptide medicines | Journal of Pharmaceutical and Biomedical Analysis | 2014 |
| 2 | RoB 2: a revised tool for assessing risk of bias in randomised trials | BMJ | 2019 |
| 3 | GRADE guidelines: 8. Rating the quality of evidence — indirectness | Journal of Clinical Epidemiology | 2011 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 8 | CELIAC-PH2B · CELIAC-PH3-CEDLARA · CELIAC-PH2B-PK · CELIAC-PH3-CEDLARA-BODY-COMP · CELIAC-PH2B-RENAL-IMP · CELIAC-PH3-CEDLARA-REGIONAL-JP · CELIAC-PH2B-HEPATIC-IMP · CELIAC-PH2B-DDI |
| Evidence syntheses | 3 | Discontinued development programmes as evidence · Larazotide acetate in inflammatory bowel disease and… · Larazotide acetate in inflammatory bowel disease and… |
| Comment periods | 1 | Draft monograph: Larazotide acetate |
| Indication assessments | 1 | Mucosal barrier |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. doi:10.1136/bmj.l4898 · PMID 31462531
- Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S, Meerpohl J, Shukla VK, Nasser M, Schünemann HJ. GRADE guidelines: 8. Rating the quality of evidence — indirectness. Journal of Clinical Epidemiology 2011;64(12):1303–1310. doi:10.1016/j.jclinepi.2011.04.014 · PMID 21802903
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.